Description
BRD4 Inhibition in Pulmonary Arterial Hypertension: a Phase 2 Clinical Trial
Amendment chain · 1 entry
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header.
- #02019-02-01$1,491,628
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2019-02-01(start date) | $1,491,628 | — | BRD4 Inhibition in Pulmonary Arterial Hypertension: a Phase 2 Clinical Trial |
Related records · 3
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (exact legal name match; no business number on file)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 236-2023-2024-Q3-00174 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada · Investigator-Initiated Research | $864,450 | FY2024 |
| 236-2018-2019-Q3-00023 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $267,750 | FY2019 |
| 236-2015-2016-Q2-00642 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $623,543 | FY2016 |
Cite as: Glassbox record view · Federal grants & contributions · 236-2018-2019-Q4-00306 · retrieved 2026-11-14.